Tilray Brands Inc vs Health Care Select Sector SPDR Fund — how do they compare? Tilray Brands Inc trades at $3.54 (market cap $530.54M), while Health Care Select Sector SPDR Fund trades at $170.48 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 82× Tilray Brands Inc's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| TLRY | XLV | |
|---|---|---|
Market Cap | $530.54M | $43.48B |
Volume | 9,099,075 | 11,121,431 |
Sector | Health | — |
52-Week High | $21.00 | $175.68 |
52-Week Low | $3.57 | $141.95 |
Typical Hold Time | 31 Days | 100 Days |
Enterprise Value | $684.46M | — |
Signals from Pluang's Aura AI — not financial advice
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
XLV trades at $170.86, up 1.21% with a bearish technical signal from moving averages while oscillators remain neutral. The healthcare ETF shows strong cost advantages with a 0.08% expense ratio compared to peers, holding 61 diversified healthcare stocks from the S&P 500. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and political volatility.
The ETF offers defensive exposure to healthcare with low costs, though technical indicators suggest near-term pressure. Key risks include sector-specific regulatory changes and election uncertainty, while the fund's diversification provides stability amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →